The Design of Inhibitors for Medicinally Relevant Metalloproteins
The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.
Abstract
A number of metalloproteins are important medicinal targets for conditions ranging from pathogenic infections to cancer. Many but not all of these metalloproteins contain a zinc(II) ion in the protein active site. Small‐molecule inhibitors of these metalloproteins are designed to bind directly to the active site metal ions. In this review several metalloproteins of interest are discussed, including matrix metalloproteinases (MMPs), histone deacetylases (HDACs), anthrax lethal factor (LF), and others. Different strategies that have been employed to design effective inhibitors against these proteins are described, with an effort to highlight the strengths and drawbacks of each approach. An emphasis is placed on examining the bioinorganic chemistry of these metal active sites and how a better understanding of the coordination chemistry in these systems may lead to improved inhibitors. It is hoped that this review will help inspire medicinal, biological, and inorganic chemists to tackle this important problem by considering all aspects of metalloprotein inhibitor design.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In most cases, a drug molecule establishes coordination bonds with the zinc ion10 present in the protein”
From AutoDock4Zn: An Improved AutoDock Force Field for Small-Molecule Docking to Zinc Metalloproteins (2014) · cites this paper as [10]
Citations
Cites
Miller, M. B., & Bassler, B. L. (2001) · Annual Review of Microbiology · doi:10.1146/annurev.micro.55.1.165 · Cited by 5,105
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
Structure and function of matrix metalloproteinases and TIMPs
NAGASE, H., VISSE, R., & MURPHY, G. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.12.002 · Cited by 3,409
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Botulinum Toxin as a Biological Weapon: Medical and Public Health Management
Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M., et al. (2001) · JAMA · doi:10.1001/jama.285.8.1059 · Cited by 1,814
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
Nelson, A. R., Fingleton, B., Rothenberg, M. L., & Matrisian, L. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1135 · Cited by 1,554
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Research works printed but not linked: 12
- Rybacki J. J., 2005, The essential guide to prescription drugs
- Stetler‐Stevenson W. G., 1996, Am. J. Pathol., 148, 1345
- Montgomery A. M., 1994, Cancer Res., 54, 5467
- Reich R., 1988, Cancer Res., 48, 3307
- Jong G. P., 2006, Chin. J. Physiol., 49, 104
- 10.1172/JCI22304 · doi:10.1172/jci22304 · Paper page
- Cataldo D. D., 2003, Cell. Mol. Biol., 49, 875
- Matter H., 2004, Curr. Opin. Drug Discovery Dev., 7, 513
- Parkkila S., 2000, The carbonic anhydrases: new horizons
- Liao S. Y., 1994, Am. J. Pathol., 145, 598
- Lewis C., 2002, FDA Consum., 36, 11
- 10.1172/JCI20195 · doi:10.1172/jci20195 · Paper page
Cited by
Items 101–155 of 155
Bourguet, E., Hornebeck, W., Sápi, J., Jean-Paul, A., & Moroy, G. (2012) · InTech eBooks · doi:10.5772/35412 · Cited by 7
“In this line, we have proposed various hydrazide and sulfonylhydrazide-type functions as potential ZBG.”
BackgroundInfluentialAbdelwahab, N. Z., Urbaniak, M. D., Ferguson, M. A. J., & Crossman, A. T. (2011) · Carbohydrate Research · doi:10.1016/j.carres.2011.02.004 · Cited by 7
Beylis, I., Frant, J., Mussai, N., Reich, R., & Breuer, E. (2008) · Tetrahedron Letters · doi:10.1016/j.tetlet.2008.03.036 · Cited by 7
Yousuf, I., & Bashir, M. (2020) · Wiley eBooks · doi:10.1002/9781119640868.ch1 · Cited by 7
Leonetti, F., Muncipinto, G., Stefanachi, A., Nicolotti, O., Cellamare, S., Catto, M., Pisani, L., Pellegrino, G., & Carotti, A. (2012) · Tetrahedron Letters · doi:10.1016/j.tetlet.2012.05.124 · Cited by 6
Haufroid, M., Volkov, A. N., & Wouters, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114935 · Cited by 6
Song, H. Y., Chung, J.-I., Jalin, A. M. A. A., Ju, C., Pahk, K., Joung, C., Lee, S., Jin, S., Kim, B. S., Lee, K. S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031403 · Cited by 6
“MMP inhibitors inactivate functional MMPs by binding specific sites at zinc domains [21].”
BackgroundRomero‐Perez, D., Agrawal, A., Jacobsen, J. A., Yan, Y., Thomas, R., Cohen, S. M., & Villarreal, F. J. (2009) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181a6aa83 · Cited by 5
“Thus, the ability to bind the zinc(II) ion in the MMPI active site is essential for the preservation of inhibitory activity.(6,19,20,52,53) It is important to note that most MMPI (including hydroxamates, carboxylates, and novel ZBG based) can also chelate other metals and thus affect other metaldependent proteases, wh…”
BackgroundMethodSelf-citationJurnečka, D., Hrovatin, M., Bokalj, B., & Turk, B. (2026) · FEBS Journal · doi:10.1111/febs.70514 · Cited by 7
“Similarly, local or targeted MMP inhibition is under investigation for aneurysm stabilisation, arthritis and corneal disease using antibodies, engineered TIMPs and prodrugs activated by pathological protease environments to minimise systemic effects [33,282,283].”
Richardson‐Sanchez, T., Tieu, W., & Codd, R. (2016) · ChemBioChem · doi:10.1002/cbic.201600636 · Cited by 4
Recent advances in therapeutical applications of the versatile hydroxypyridinone chelators
Sharma, S., Baral, M., & Kanungo, B. K. (2022) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/s10847-021-01114-1 · Cited by 4
Nitro-based selective inhibitors against matrix metalloproteinase-7 over matrix metalloproteinase-1
Li, M., Zhang, Y., Tian, H., Zheng, M., Yang, M.-Y., Fang, H.-L., Xie, Y., & Jin, J. (2015) · RSC Advances · doi:10.1039/c5ra22271k · Cited by 4
Usmanova, Z., & Tashkent, U. (2015) · International Journal of Biomedicine · doi:10.21103/article5(2)_cr2 · Cited by 4
“The catalytic domain of all MMPs contains a Zn2+ ion coordinated by a tris(histidine) motif; the Zn2+ ion is critical for both substrate binding and cleavage [9-11].”
BackgroundHybrid quantum/classical docking of covalent and non-covalent ligands with Attracting Cavities
Goullieux, M., Zoete, V., & Röhrig, U. F. (2025) · Scientific Reports · doi:10.1038/s41598-025-24614-3 · Cited by 5
Nitro-based inhibitors against thermolysin
Tian, G. R., Wang, S., Wang, S., Meng, L., Li, H., Zeng, Z.-H., & Jin, J. (2011) · MedChemComm · doi:10.1039/c1md00088h · Cited by 3
Fluorescence-Based Methods to Assay Inhibitors of Lipopolysaccharide Synthesis
Hernick, M. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-102-4_11 · Cited by 3
Drug Design of Sulfonylated MMP Inhibitors
Rossello, A., & Nuti, E. (2009) · doi:10.1002/9780470508169.ch25 · Cited by 3
Scheithauer, L., Ornago, C., Selmar, J., Schütz, C., Bianchi, G., Kiefer, A. F., Haupenthal, J., Dellmann, A., Huynh, D., Zhang, R., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117832 · Cited by 2
Cyclic and Non-Cyclic Pi Complexes of Molybdenum
Wang, W., Zhai, X., & Hou, S.-F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820206-7.00031-7 · Cited by 2
Yeast-hybrid based high-throughput assay for identification of anthrax lethal factor inhibitors
Kim, J., Park, H., Gedi, V., Park, H.-Y., Roberts, A. G., Atkins, W. M., & Yoon, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.015 · Cited by 2
“Considering that most of the current LF inhibitors interact with the LF active site (domain III and IV) to inhibit LF proteolytic activity [24], and reviewed in [25], FBS-00831 has a potential advantage over other inhibitors due to its dual function.”
BackgroundBerreau, L. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-08-097774-4.00310-7 · Cited by 1
Mechanisms of Metal-Dependent Hydrolases in Metabolism
Hernick, M., & Fierke, C. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.02882-1 · Cited by 2
MMP Inhibitors Based on Earlier Succinimide Strategies: From Early to New Approaches
Santos, M. A. (2009) · doi:10.1002/9780470508169.ch24 · Cited by 1
The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes
Ganesan, A. (2012) · Wiley eBooks · doi:10.1002/9783527651085.ch5
Design of Metalloprotease Inhibitors
Ghosh, A. K., & Gemma, S. (2014) · doi:10.1002/9783527665211.ch6
Kinetic and docking studies of inhibitors targeting the catalytic zinc in MA clan enzymes
Sjøli, S. (2011) · NORA - Norwegian Open Research Archives · Cited by 1
Effects of metalloprotease anthrax lethal factor on its peptide-based inhibitor R9LF-1
Kong, Q., Song, Y., Mu, M., Han, X., Si, C., & Li, F. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2447-6
“Peptidic LF inhibitors usually contain substrate-like amino acid sequences and a C-terminal component, such as a hydroxamic acid, which has been widely used in most metalloprotease inhibitors including LF with the function to chelate the divalent ions such as Zn ion in the active site [17].”
Backgroundda Rocha, L. D. A. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2017.tde-20072016-115252
Receptor Binding Domains and Coronavirus Adaptation and Evolution
Wong, A. H. M. (2018) · TSpace (University of Toronto)
Acetogenins from Annona coriacea Target TNFR1-Mediated Cell Death in Head and Neck Cancer
Cordeiro, G. A. R., Oliveira, A. G. S., Junqueira, J. G. M., Sousa, L. R., Gonçalves, A. D. S., Asevedo, E. A., Ribeiro, R. E. M., Reis, R. M., Severino, V. G. P., Thome, R. G., et al. (2026) · ACS Omega · doi:10.1021/acsomega.6c02820
Thiols and Their Derivatives: Synthesis, Reactivity and Anticancer Applications
Demirci, S. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1018138
BindingDB Entry 50031847: MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.
BindingDB (2010) · UC San Diego · doi:10.7270/q28052s4
BindingDB (2013) · UC San Diego · doi:10.7270/q2cz38j9
BindingDB (2012) · UC San Diego · doi:10.7270/q2h70gn0
BindingDB Entry 7929: Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.
BindingDB (2017) · UC San Diego · doi:10.7270/q24j0d0b
Metadata
- Authors
- Jacobsen, F. E., Lewis, J. A., & Cohen, S. M.
- Affiliations
- University of California San Diego (US)
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2007-01-30
- Volume
- 2
- Issue
- 2
- Pages
- 152-171
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2102128466
- Cited by
- 132
- References
- 175
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 2 · 2018: 5 · 2017: 9 · 2016: 6 · 2015: 11 · 2014: 7 · 2013: 8 · 2012: 15
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- ChemMedChem (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- small molecule inhibitors, matrix metalloproteinases, histone deacetylase, anthrax lethal factor, bioinorganic chemistry, coordination chemistry
- MeSH terms
- Animals, Binding Sites, Catalysis, Cells, Cultured, Fibroblasts, Humans, Metalloproteins, Protease Inhibitors, Protein Conformation, Spectrum Analysis, Structure-Activity Relationship, Zinc, Drug Design, Inhibitory Concentration 50, Matrix Metalloproteinases, Myoblasts, Cardiac, Matrix Metalloproteinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.